Cargando…
Association of BDNF, HTR2A, TPH1, SLC6A4, and COMT polymorphisms with tDCS and escitalopram efficacy: ancillary analysis of a double-blind, placebo-controlled trial
OBJECTIVE: We investigated whether single nucleotide polymorphisms (SNPs) associated with neuroplasticity and activity of monoamine neurotransmitters, such as the brain-derived neurotrophic factor (BDNF, rs6265), the serotonin transporter (SLC6A4, rs25531), the tryptophan hydroxylase 1 (TPH1, rs1800...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Associação Brasileira de Psiquiatria
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7115450/ https://www.ncbi.nlm.nih.gov/pubmed/31721892 http://dx.doi.org/10.1590/1516-4446-2019-0620 |
_version_ | 1783514100155809792 |
---|---|
author | Brunoni, Andre R. Carracedo, Angel Amigo, Olalla M. Pellicer, Ana L. Talib, Leda Carvalho, Andre F. Lotufo, Paulo A. Benseñor, Isabela M. Gattaz, Wagner Cappi, Carolina |
author_facet | Brunoni, Andre R. Carracedo, Angel Amigo, Olalla M. Pellicer, Ana L. Talib, Leda Carvalho, Andre F. Lotufo, Paulo A. Benseñor, Isabela M. Gattaz, Wagner Cappi, Carolina |
author_sort | Brunoni, Andre R. |
collection | PubMed |
description | OBJECTIVE: We investigated whether single nucleotide polymorphisms (SNPs) associated with neuroplasticity and activity of monoamine neurotransmitters, such as the brain-derived neurotrophic factor (BDNF, rs6265), the serotonin transporter (SLC6A4, rs25531), the tryptophan hydroxylase 1 (TPH1, rs1800532), the 5-hydroxytryptamine receptor 2A (HTR2A, rs6311, rs6313, rs7997012), and the catechol-O-methyltransferase (COMT, rs4680) genes, are associated with efficacy of transcranial direct current stimulation (tDCS) in major depression. METHODS: Data from the Escitalopram vs. Electrical Current Therapy for Treating Depression Clinical Study (ELECT-TDCS) were used. Participants were antidepressant-free at baseline and presented with an acute, moderate-to-severe unipolar depressive episode. They were randomized to receive escitalopram/tDCS-sham (n=75), tDCS/placebo-pill (n=75), or placebo-pill/sham-tDCS (n=45). General linear models assessed the interaction between treatment group and allele-wise carriers. Additional analyses were performed for each group and each genotype separately. RESULTS: Pairwise group comparisons (tDCS vs. placebo, tDCS vs. escitalopram, and escitalopram vs. placebo) did not identify alleles associated with depression improvement. In addition, exploratory analyses also did not identify any SNP unequivocally associated with improvement of depression in any treatment group. CONCLUSION: Larger, combined datasets are necessary to identify candidate genes for tDCS response. |
format | Online Article Text |
id | pubmed-7115450 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Associação Brasileira de Psiquiatria |
record_format | MEDLINE/PubMed |
spelling | pubmed-71154502020-04-03 Association of BDNF, HTR2A, TPH1, SLC6A4, and COMT polymorphisms with tDCS and escitalopram efficacy: ancillary analysis of a double-blind, placebo-controlled trial Brunoni, Andre R. Carracedo, Angel Amigo, Olalla M. Pellicer, Ana L. Talib, Leda Carvalho, Andre F. Lotufo, Paulo A. Benseñor, Isabela M. Gattaz, Wagner Cappi, Carolina Braz J Psychiatry Original Article OBJECTIVE: We investigated whether single nucleotide polymorphisms (SNPs) associated with neuroplasticity and activity of monoamine neurotransmitters, such as the brain-derived neurotrophic factor (BDNF, rs6265), the serotonin transporter (SLC6A4, rs25531), the tryptophan hydroxylase 1 (TPH1, rs1800532), the 5-hydroxytryptamine receptor 2A (HTR2A, rs6311, rs6313, rs7997012), and the catechol-O-methyltransferase (COMT, rs4680) genes, are associated with efficacy of transcranial direct current stimulation (tDCS) in major depression. METHODS: Data from the Escitalopram vs. Electrical Current Therapy for Treating Depression Clinical Study (ELECT-TDCS) were used. Participants were antidepressant-free at baseline and presented with an acute, moderate-to-severe unipolar depressive episode. They were randomized to receive escitalopram/tDCS-sham (n=75), tDCS/placebo-pill (n=75), or placebo-pill/sham-tDCS (n=45). General linear models assessed the interaction between treatment group and allele-wise carriers. Additional analyses were performed for each group and each genotype separately. RESULTS: Pairwise group comparisons (tDCS vs. placebo, tDCS vs. escitalopram, and escitalopram vs. placebo) did not identify alleles associated with depression improvement. In addition, exploratory analyses also did not identify any SNP unequivocally associated with improvement of depression in any treatment group. CONCLUSION: Larger, combined datasets are necessary to identify candidate genes for tDCS response. Associação Brasileira de Psiquiatria 2019-11-11 /pmc/articles/PMC7115450/ /pubmed/31721892 http://dx.doi.org/10.1590/1516-4446-2019-0620 Text en http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Brunoni, Andre R. Carracedo, Angel Amigo, Olalla M. Pellicer, Ana L. Talib, Leda Carvalho, Andre F. Lotufo, Paulo A. Benseñor, Isabela M. Gattaz, Wagner Cappi, Carolina Association of BDNF, HTR2A, TPH1, SLC6A4, and COMT polymorphisms with tDCS and escitalopram efficacy: ancillary analysis of a double-blind, placebo-controlled trial |
title | Association of BDNF, HTR2A, TPH1, SLC6A4, and COMT polymorphisms with tDCS and escitalopram efficacy: ancillary analysis of a double-blind, placebo-controlled trial |
title_full | Association of BDNF, HTR2A, TPH1, SLC6A4, and COMT polymorphisms with tDCS and escitalopram efficacy: ancillary analysis of a double-blind, placebo-controlled trial |
title_fullStr | Association of BDNF, HTR2A, TPH1, SLC6A4, and COMT polymorphisms with tDCS and escitalopram efficacy: ancillary analysis of a double-blind, placebo-controlled trial |
title_full_unstemmed | Association of BDNF, HTR2A, TPH1, SLC6A4, and COMT polymorphisms with tDCS and escitalopram efficacy: ancillary analysis of a double-blind, placebo-controlled trial |
title_short | Association of BDNF, HTR2A, TPH1, SLC6A4, and COMT polymorphisms with tDCS and escitalopram efficacy: ancillary analysis of a double-blind, placebo-controlled trial |
title_sort | association of bdnf, htr2a, tph1, slc6a4, and comt polymorphisms with tdcs and escitalopram efficacy: ancillary analysis of a double-blind, placebo-controlled trial |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7115450/ https://www.ncbi.nlm.nih.gov/pubmed/31721892 http://dx.doi.org/10.1590/1516-4446-2019-0620 |
work_keys_str_mv | AT brunoniandrer associationofbdnfhtr2atph1slc6a4andcomtpolymorphismswithtdcsandescitalopramefficacyancillaryanalysisofadoubleblindplacebocontrolledtrial AT carracedoangel associationofbdnfhtr2atph1slc6a4andcomtpolymorphismswithtdcsandescitalopramefficacyancillaryanalysisofadoubleblindplacebocontrolledtrial AT amigoolallam associationofbdnfhtr2atph1slc6a4andcomtpolymorphismswithtdcsandescitalopramefficacyancillaryanalysisofadoubleblindplacebocontrolledtrial AT pelliceranal associationofbdnfhtr2atph1slc6a4andcomtpolymorphismswithtdcsandescitalopramefficacyancillaryanalysisofadoubleblindplacebocontrolledtrial AT talibleda associationofbdnfhtr2atph1slc6a4andcomtpolymorphismswithtdcsandescitalopramefficacyancillaryanalysisofadoubleblindplacebocontrolledtrial AT carvalhoandref associationofbdnfhtr2atph1slc6a4andcomtpolymorphismswithtdcsandescitalopramefficacyancillaryanalysisofadoubleblindplacebocontrolledtrial AT lotufopauloa associationofbdnfhtr2atph1slc6a4andcomtpolymorphismswithtdcsandescitalopramefficacyancillaryanalysisofadoubleblindplacebocontrolledtrial AT bensenorisabelam associationofbdnfhtr2atph1slc6a4andcomtpolymorphismswithtdcsandescitalopramefficacyancillaryanalysisofadoubleblindplacebocontrolledtrial AT gattazwagner associationofbdnfhtr2atph1slc6a4andcomtpolymorphismswithtdcsandescitalopramefficacyancillaryanalysisofadoubleblindplacebocontrolledtrial AT cappicarolina associationofbdnfhtr2atph1slc6a4andcomtpolymorphismswithtdcsandescitalopramefficacyancillaryanalysisofadoubleblindplacebocontrolledtrial |